GWP.L Regulatory News (GWP)

17 Sep 2009 07:00



GW Pharmaceuticals to host update on cannabinoid pipeline

Porton Down, UK, 17 September 2009: GW Pharmaceuticals plc (GWP:AIM), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, will today host an R&D update meeting for analysts at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB.

The focus of the R&D update will be GW's earlier stage cannabinoid research programmes and the company will be joined by some of its external scientific collaborators. The update will not include any material new information on the cannabinoid research programme or on Sativex.

-- Ends --

Enquiries: 

Notes to Editors

About GW

GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For more information, visit www.gwpharm.com 

About GW's R&D programme 

Under a global research collaboration agreement with Otsuka Pharmaceutical Co. Ltd, senior scientists from both companies are directing research into a range of GW cannabinoids as drug candidates within CNS and oncology. Promising new psychiatric, neurological and oncologic drug candidates have been identified and these are expected to be a principal focus for the next phase of the collaboration. GW has also carried out pre-clinical research on its cannabinoids in several models of diabetes and is now preparing to advance a novel cannabinoid THCV:CBD drug candidate into a Phase IIa multiple dose study in the treatment of dyslipidaemia and fatty liver in Type II diabetic patients. The company has recently entered into an exclusive strategic alliance with Professor Mike Cawthorne, the scientist who invented rosiglitazone (Avandia®), and the Clore Laboratory, University of Buckingham, focusing on the research of cannabinoids, and potentially other phytomedicines, in the field of metabolic disease.